Articles

Medical Education

May 14, 2025

Combining Traditional and Modern Medicine: My Approach to Treating Pancreatic Cancer

Pancreatic cancer is one of the most aggressive and challenging cancers to treat, often diagnosed in its advanced stages and associated with a low survival rate. Over the years, advancements in modern medicine have led to improved diagnostic techniques, surgical procedures, and targeted therapies. However, as both a medical professional and a believer in holistic healing, I have come to understand the value of integrating traditional medicine with modern approaches to offer a more comprehensive and personalized treatment plan for pancreatic cancer.

Understanding the Challenge of Pancreatic Cancer

Pancreatic cancer is notoriously difficult to detect early. Its symptoms are often vague—such as abdominal pain, weight loss, and jaundice—and may be attributed to less serious illnesses. This delay in diagnosis means that, in most cases, the cancer has already spread beyond the pancreas. Standard treatments include surgery (when possible), chemotherapy, radiation therapy, and more recently, immunotherapy and precision medicine.

Despite these options, outcomes remain poor for many patients, leading us to ask: What more can we do?

Why Combine Traditional and Modern Medicine?

Modern medicine focuses on eradicating cancer cells and prolonging life through scientifically tested methods. However, it can also bring harsh side effects—fatigue, nausea, compromised immunity, and mental stress. Traditional medicine, including herbal remedies, acupuncture, dietary therapy, yoga, and meditation, has long been used in various cultures to improve overall well-being.

Combining these approaches does not mean choosing one over the other; rather, it’s about creating a collaborative treatment framework that treats the disease while also supporting the mind, body, and spirit.

My Integrated Approach

  1. Modern Diagnosis and Treatment as the Foundation: The cornerstone of my approach is evidence-based modern treatment. Accurate diagnosis through imaging and biopsy, followed by chemotherapy, radiation, or surgery (depending on the stage), is always the first step. I work closely with oncologists to ensure that every patient receives the most appropriate standard care.
  2. Nutritional Therapy from Traditional Systems: In many traditional medical systems such as Ayurveda and Traditional Chinese Medicine (TCM), food is considered medicine. I incorporate anti-inflammatory and immune-boosting diets rich in antioxidants, turmeric, ginger, green leafy vegetables, and whole grains to support the patient’s strength during chemotherapy.
  3. Herbal and Natural Supplements: Under strict supervision and with careful research, I sometimes include herbal supplements like curcumin (from turmeric), ashwagandha, or milk thistle, known for their potential anti-cancer properties. These are introduced only after ensuring they don’t interfere with ongoing medications or treatments.
  4. Mind-Body Practices: Stress has a direct impact on a patient’s recovery journey. I encourage meditation, breathing exercises, and yoga to promote relaxation, reduce anxiety, and enhance mental clarity. This improves not just quality of life but can also positively affect treatment response.
  5. Acupuncture and Pain Management: For patients dealing with chronic pain, nausea, or neuropathy due to chemotherapy, acupuncture can offer substantial relief. It is a non-invasive option that many patients find comforting and effective.
  6. Spiritual and Community Support: Healing is not just physical—it’s emotional and spiritual. I advocate for patients to engage in spiritual practices, community healing circles, or counseling sessions. Emotional resilience often plays a crucial role in how a patient copes with the disease.

The Benefits of a Combined Approach

Patients treated with an integrated approach often report better symptom management, reduced side effects, and an improved sense of control over their healing process. Most importantly, it allows them to maintain dignity and hope during a time that is often filled with uncertainty.

Conclusion

While modern medicine provides the tools to fight pancreatic cancer at the cellular level, traditional medicine supports the patient as a whole person. By combining both, we offer a more compassionate, personalized, and potentially more effective path to treatment. As we continue to advance in medical science, the future of cancer treatment should embrace both the ancient wisdom of healing and the cutting-edge innovations of modern therapy—for they are not opponents, but allies in the fight against cancer.

Combining Traditional and Modern Medicine: My Approach to Treating Pancreatic Cancer

Cancer Treatment

May 14, 2025

Combining Traditional and Modern Medicine: My Approach to Treating Pancreatic Cancer

As a surgeon and researcher, I’ve always believed in the power of blending traditional medicine with cutting-edge scientific treatments.

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer

May 16, 2019

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer

Prostate cancer (PCA) remains a significant health challenge worldwide, necessitating innovative therapeutic strategies. Combination chemotherapy, utilizing multiple chemotherapeutic agents, has shown promise in enhancing treatment efficacy. However, differences in the pharmacokinetics of these drugs often hinder their synergistic potential. To address this, our study explores the co-delivery of docetaxel (DOC) and doxorubicin (DOX) using nanocarriers, aiming to optimize their combined therapeutic effects against PCA.

Design and Characterization of DDC Nanoparticles

We developed DOC and DOX co-delivery nanoparticles (DDC NPs) through a self-assembly process involving hyaluronic acid (HA) and cationic amphipathic starch (CSaSt). Transmission electron microscopy revealed that these nanoparticles are spherical with rough surfaces, averaging 68.4 ± 7.1 nm in size and possessing a zeta potential of -22.8 ± 2.2 mV. The encapsulation efficiencies for DOC and DOX were 96.1 ± 2.3% and 91.4 ± 3.7%, respectively, with a total drug loading of 9.1 ± 1.7%. Importantly, the DOC to DOX ratio within the nanoparticles was approximately 1:400, aligning with the optimal synergistic proportions identified in our study.

In Vitro Efficacy

The DDC NPs demonstrated sustained and enzymatic drug release while maintaining stability in phosphate-buffered saline (PBS), culture medium, and serum. In vitro assays using human PCA cell lines (PC-3, DU-145, and LNCap) indicated that DDC NPs were as effective as the dual drug combination in inducing cytotoxicity, inhibiting cell migration, and promoting apoptosis. The internalization of DDC NPs by PCA cells was facilitated by the interaction between HA and the CD44 receptor, ensuring efficient delivery and release of the therapeutic agents within the target cells.

In Vivo Therapeutic Outcomes

In vivo studies utilizing PCA cell xenograft mouse models revealed that DDC NPs significantly enhanced the accumulation of DOC and DOX in tumor tissues while reducing nonspecific distribution in normal organs. This targeted delivery resulted in a notable improvement in therapeutic efficacy, with DDC NPs promoting greater tumor suppression compared to free drug combinations. Furthermore, acute toxicity and hemolytic assays confirmed the low toxicity profile of DDC NPs, underscoring their potential for safe clinical application.

Conclusion

Our findings suggest that the co-delivery of DOC and DOX via HA-CSaSt-based nanoparticles offers a promising approach for synergistic chemotherapy in prostate cancer treatment. The DDC NPs not only optimize the therapeutic ratio of the drugs but also enhance their delivery to tumor sites while minimizing systemic toxicity. This nanocarrier system holds significant potential for advancing PCA chemotherapy and warrants further clinical investigation.

Applications of Memory Alloy Stents in Vertebral Fractures

May 16, 2015

Applications of Memory Alloy Stents in Vertebral Fractures

Vertebral compression fractures (VCFs) are prevalent injuries that can lead to significant pain, reduced mobility, and diminished quality of life. Traditional treatments, such as percutaneous vertebroplasty and kyphoplasty, have been effective but come with limitations, including the risk of cement leakage and insufficient restoration of vertebral height. In response to these challenges, our study explores the use of nitinol memory alloy stents as a novel approach to treating VCFs.

Study Overview

This research aimed to assess the feasibility and effectiveness of using nitinol memory alloy stents in the management of VCFs. Nitinol, known for its superelasticity and shape memory properties, offers the potential to provide dynamic support to fractured vertebrae, promoting better stabilization and alignment.

Methodology

In our study, patients with diagnosed VCFs underwent a minimally invasive procedure where nitinol memory alloy stents were implanted into the affected vertebral bodies. The stents were designed to expand within the vertebral body, providing internal support and aiding in the restoration of vertebral height. Postoperative evaluations included imaging studies to assess vertebral alignment and patient-reported outcomes to gauge pain relief and functional improvement.

Findings

The implantation of nitinol memory alloy stents resulted in significant restoration of vertebral height and alignment. Patients reported substantial pain relief and improved mobility in the postoperative period. Importantly, the procedure demonstrated a low incidence of complications, with no significant cases of cement leakage or adjacent vertebral fractures observed during the follow-up period.

Conclusion

The use of nitinol memory alloy stents presents a promising advancement in the treatment of vertebral compression fractures. By providing internal support and promoting vertebral height restoration, these stents can enhance patient outcomes and reduce the risks associated with traditional treatments. Further studies with larger patient populations and longer follow-up periods are warranted to fully establish the efficacy and safety profile of this innovative approach.